European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-27

European (euro) network for development of novel safe vaccines based on new generation amplicons (amp) and other defective hsv-1 derived vectors as foreign antigen delivery systems.

Objective

Seven European laboratories have associated to evaluate the potential of defective HSV vectors, including helper-free HSV amplicons, as vaccine for the delivery of foreign antigens. The model antigens will be derived from human viruses of high public health concern, such as HCV, HIV-1 and HPV-16, each causing significant morbidity and mortality and substantial economic burden. No effective vaccines are available to prevent or treat these viral infections. To this end we plan to determine the conditions required to optimise delivery, expression and presentation of foreign antigens, including the in vivo synthesis of empty virus-like HCV and HPV-16 particles. Significant innovations will be the use of a unique in its nature vector (the amplicon), never used before, as vaccine vector and the attempt to manipulate the immune response by attracting monocytes to sites of infection and inducing their differentiation into dendritic cells.

Call for proposal

Data not available

Coordinator

UNIVERSITE CLAUDE BERNARD LYON 1
EU contribution
No data
Address
43,Boulevard du 11 Novembre 1918, 43
69622 VILLEURBANNE
France

See on map

Total cost
No data

Participants (5)